Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
781-800 of 998 trials

Metastatic Colorectal Cancer: S 95005 with Bevacizumab

We are studying a new treatment combination for patients with metastatic colorectal cancer who cannot receive intensive therapy. The goal is to see if it helps patients live longer without disease progression compared to standard treatment.

Metastatic Colorectal Cancer1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Stroke Prevention: ASPIRING Study

We are investigating if an oral antiplatelet drug can help prevent serious heart and brain events in stroke survivors. This study compares the effects of this medication to standard care without antiplatelet drugs.

Intracerebral Hemorrhage>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal MedicineNeurology

Glioblastoma Multiforme: Long-Term Safety of Temferon

We are monitoring the long-term safety and effects of Temferon in patients who have been treated for glioblastoma multiforme. This study aims to understand any potential side effects and how the disease may progress.

Glioblastoma MultiformeSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteNeurologyOncology

B-Cell Malignancies: BGB-16673 Treatment Study

We are investigating the safety and effectiveness of BGB-16673 combined with other treatments for patients with relapsed or refractory B-cell malignancies. This study aims to find the best dose and assess how well the treatment works.

Relapsed or Refractory B-Cell Malignancies>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Acute Demyelinating Syndromes in Children: Azathioprine vs. Rituximab

We are studying whether starting treatment immediately with azathioprine or rituximab helps children with anti-MOG antibodies better than delaying treatment until a second attack. The goal is to see which method reduces relapses and improves health outcomes.

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyRheumatology

Hereditary Angioedema: Deucrictibant Tablet Study

We are evaluating a new oral medication to prevent angioedema attacks in adolescents and adults with hereditary angioedema. The study aims to determine its effectiveness and safety compared to a placebo.

Hereditary Angioedema3-6 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine

Hereditary Angioedema: Deucrictibant Extended-Release Tablet

We are studying a new oral medication to prevent angioedema attacks in adolescents and adults with hereditary angioedema. The trial will evaluate its safety, effectiveness, and impact on quality of life.

Hereditary Angioedema>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine

Liver Cirrhosis: RTX001 Macrophage Therapy

We are studying a new treatment using RTX001 autologous macrophages for people with decompensated liver cirrhosis. The trial aims to evaluate its safety and effectiveness in improving liver function.

Liver Cirrhosis>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHepatologyInternal Medicine

Prucalopride for Refractory Gastro-Esophageal Reflux Disease

We are testing a new medication for patients with GERD who still have symptoms despite taking standard treatments. The goal is to see if this drug can improve their reflux symptoms.

Gastro-esophageal Reflux Disease (GERD)≤3 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Knee Osteoarthritis: Bovine vs. Marine Chondroitin Sulfate

We are comparing two types of chondroitin sulfate tablets to see if they help reduce pain and improve function in people with knee osteoarthritis. This study will also look at how these treatments affect quality of life and safety.

Knee Osteoarthritis6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOrthopedics and TraumatologyRheumatology

Pegcetacoplan for Adolescents with Paroxysmal Nocturnal Hemoglobinuria

We are studying the safety and biological activity of pegcetacoplan in patients aged 12-17 with PNH. This trial will help us understand how well the treatment works and its effects on health-related quality of life.

Paroxysmal Nocturnal Hemoglobinuria3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematology

Chronic Urticaria: Testing Remibrutinib

We are exploring whether remibrutinib can help adults with Chronic Urticaria manage their symptoms better than a placebo. The study also looks at the safety of this new treatment and its effects on quality of life.

Chronic Urticaria≤3 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteAllergologyDermatology

Complicated Urinary Tract Infections in Children: Vabomere Study

We are studying the safety and effectiveness of Vabomere for children aged 3 months to under 12 years with complicated urinary tract infections. This research aims to improve treatment options for these young patients.

Complicated Urinary Tract InfectionAcute Pyelonephritis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesUrology

Alzheimer’s Disease: KarXT for Psychosis

We are testing a new treatment called KarXT for people with psychosis associated with Alzheimer’s disease. The study aims to see if it can reduce symptoms like hallucinations and delusions compared to a placebo.

Psychosis Associated with Alzheimer's Disease3-6 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Post-COVID-19 Condition: Plitidepsin Study

We are investigating whether plitidepsin can improve health outcomes for adults with post-COVID-19 Condition. The study will compare its effects to a placebo on symptoms and overall well-being.

Post-COVID-19 Syndrome3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteCardiologyDiabetologyEndocrinologyGastroenterologyHematologyInfectious DiseasesInternal MedicineNeurologyPsychiatryPulmonologyRheumatology

Soft Tissue Sarcoma: Trabectedin with tTF-NGR

We are studying a new treatment combining trabectedin with tTF-NGR for patients with advanced soft tissue sarcoma. The goal is to see if this combination helps patients live longer without disease progression compared to trabectedin alone.

Metastatic Soft-Tissue Sarcoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteOncology

Immune Thrombocytopenia: Dexamethasone vs. IVIg

We are studying whether oral dexamethasone is as effective as intravenous immunoglobulin combined with prednisone for adults with immune thrombocytopenia experiencing bleeding. This research may help identify a more convenient treatment option.

Immune Thrombocytopenia>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyInternal Medicine

Sepsis Treatment: Hydrocortisone and Fludrocortisone Study

We are investigating whether a combination of hydrocortisone and fludrocortisone can improve outcomes for adults with sepsis in the ICU. This study aims to see if it helps reduce death or ongoing organ issues compared to a placebo.

Sepsis>2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Bariatric Surgery: Metformin for Diabetes Management

We are studying whether adding metformin to standard care helps people who had bariatric surgery stay diabetes-free longer. This trial focuses on former type 2 diabetes patients and their overall health and quality of life.

Type 2 Diabetes>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteEndocrinologyInternal Medicine

Seizures in Developmental and Epileptic Encephalopathies: LP352 Study

We are investigating whether LP352 can help reduce seizures in children and adults with developmental and epileptic encephalopathies. This study compares the medication to a placebo to assess its effectiveness and safety.

Developmental and Epileptic EncephalopathiesConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics